文献速递白血病

IGJ与SPATS2L免疫组化敏感且特异地识别BCR::ABL1阳性及BCR::ABL1样B细胞急性淋巴细胞白血病

IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2023-10-23

研究纳入来自三家机构、两个实验室共118例B-ALL病例,评估免疫组化(IHC)检测免疫球蛋白连接链(IGJ)和SPATS2L能否替代分子/细胞遗传学方法识别BCR::ABL1阳性/样B-ALL。结果显示IGJ IHC敏感度83%、特异度95%,SPATS2L特异度较低(85%),任一染色阳性可将敏感度提升至93%、阴性预测值95%。作者认为这些发现需在更大研究中验证。

要点

  • IGJ IHC识别BCR::ABL1阳性/样B-ALL的敏感度83%、特异度95%、阳性预测值89%、阴性预测值90%。
  • SPATS2L染色敏感度与阴性预测值类似,但特异度(85%)和阳性预测值(70%)较低。
  • IGJ或SPATS2L任一染色阳性可提高敏感度至93%、阴性预测值至95%。

核心结论

  • IGJ和SPATS2L免疫组化可敏感且特异地识别BCR::ABL1阳性/样B-ALL,但需在更大研究中验证。

研究设计与样本

  • 研究共纳入来自三家机构、两个实验室的118例B-ALL病例,以寻找BCR::ABL1阳性/样B-ALL的替代标志物。

主要发现

  • IGJ IHC阳性识别BCR::ABL1阳性/样B-ALL的敏感度为83%、特异度为95%、阳性预测值为89%、阴性预测值为90%。
  • SPATS2L染色具有与IGJ相似的敏感度和阴性预测值,但特异度较低(85%)、阳性预测值较低(70%)。
  • IGJ或SPATS2L任一染色阳性可将敏感度提高至93%、阴性预测值提高至95%。

关键数值与推荐

  • IGJ IHC阳性:敏感度83%、特异度95%、阳性预测值89%、阴性预测值90%。
  • SPATS2L染色:敏感度与阴性预测值与IGJ相似,特异度85%、阳性预测值70%。
  • IGJ或SPATS2L任一染色阳性:敏感度93%、阴性预测值95%。

临床怎么用

  • 作者认为IGJ和/或SPATS2L免疫组化可用于识别BCR::ABL1样B-ALL或选择B-ALL病例进行确诊性分子/遗传学检测,尤其在资源有限的环境中。

局限性

  • 原文指出这些发现需要在更大规模的研究中进行验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic management and prognostication for patients with B-acute lymphoblastic leukaemia (B-ALL) require appropriate disease subclassification. BCR::ABL1-like B-ALL is unique in that it is defined by a gene expression profile similar to BCR::ABL1+ B-ALL rather than a unifying recurrent translocation. Current molecular/cytogenetic techniques to identify this subtype are expensive, not widely accessible, have long turnaround times and/or require an adequate liquid biopsy. We have studied a total of 118 B-ALL cases from three institutions in two laboratories to identify surrogates for BCR::ABL1+/like B-ALL. We report that immunoglobulin joining chain (IGJ) and spermatogenesis associated serine-rich 2-like (SPATS2L) immunohistochemistry (IHC) sensitively and specifically identify BCR::ABL1+/like B-ALL. IGJ IHC positivity has a sensitivity of 83%, a specificity of 95%, a positive predictive value (PPV) of 89% and a negative predictive value (NPV) of 90%. SPATS2L staining has similar sensitivity and NPV but lower specificity (85%) and PPV (70%). The presence of either IGJ or SPATS2L staining augments the sensitivity (93%) and NPV (95%). While these findings would need to be validated in larger studies, they suggest that IGJ and/or SPATS2L IHC may be utilized in identifying BCR::ABL1-like B-ALL or in selecting B-ALL cases for confirmatory molecular/genetic testing, particularly in resource-limited settings.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gestrich CK, De Lancy SJ, Kresak A, et al. IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia. Br J Haematol. 2023. PMID: 37871900. doi:10.1111/bjh.19142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。